Biotech Values

[dewophile]

I'm not following but it is not important
here is the presentation from the VIR website. It seems all patients at week 48 without detectable surface antigen were also positive for surface antibody - i.e. there are no patients to speak of who are both surface antigen negative but also antibody negative. There was one patient in cohort 4 who reverted at week 48 but it doesn't specify if this patient was also antibody positive.
If this 30% holds over larger patient numbers and off treatment they may have something, but the fact they could not shorten duration of interferon therapy at all below one year makes me think the drug is not as active as it would seem by looking at just the cohort 5 data

https://investors.vir.bio/static-files/cc0a3c3b-43f0-42ff-82a8-077dee7ab339

edit: 10 patients in total in all cohorts were surface antigen negative at some point. 9 of the 10 also were antibody positive. 8 patients were negative at week 48, all of whom were also antibody positive. so 1/9 patients who were antibody positive on treatment reverted by EOT, and 1/1 patient who was antibody negative reverted. fwiw